AOA Dx GTM brain

category

market profile

• text: Omira OC is under development for symptomatic women; it should not be represented as a general population screening test or as clinically available without confirmation.
• text: The OVERT prospective study is gathering samples from women with signs or symptoms to assess test accuracy.
• text: Clinical adoption depends on evidence, intended use, regulation and reimbursement, with several other companies developing ovarian assays.

personas

• title: OB-GYN or primary care clinician
  pains:

  • Nonspecific symptoms make decisions about further ovarian cancer evaluation difficult.
  • Clinicians need credible test performance and a clear next-step pathway before ordering.
• title: Gynecologic oncology and diagnostic program lead
  pains:

  • Patients may arrive after long diagnostic workups.
  • New assays require evidence in the intended population and a pathway to specialist evaluation.
• title: Clinical laboratory medical director
  pains:

  • Needs assay validation, specimen handling details and operational feasibility.
  • Requires clarity on regulatory status, reimbursement and clinical utility.

icp

• text: Health systems with women's health, gynecology and oncology pathways treating symptomatic patients are plausible future users; commercial size thresholds are not established.
• text: Clinical research sites and diagnostic laboratories able to recruit appropriate patients and assess blood-based biomarkers are potential study and development partners.

message pillars

• text: Focus on women's health and earlier cancer detection.
• text: Combine blood testing, AI and multi-omics.
• text: Explore lipidomics for new biomarkers.

objections

• objection: Is the test validated for my patients and available for clinical use?
  response: Review current study design, intended population, regulatory status and availability with AOA before considering adoption.
• objection: How will false results, referrals and payment be handled?
  response: Discuss performance at the relevant threshold, clinical workflow and reimbursement with the company and institutional leadership.

competitors

• name: Aspira Women's Health
  why: Develops ovarian risk assessment tests, though indications and stages of development differ.
• name: Cleo Diagnostics
  why: Develops ovarian cancer diagnostic assays.
• name: Mercy BioAnalytics
  why: Develops tests for ovarian cancer detection.
• name: ClearNote Health
  why: Listed among companies developing ovarian cancer diagnostic assays.

influencers

• name: Kevin Elias
  url: https://www.aoadx.com/about/
  why: Principal investigator for the OVERT clinical study.
• name: Oriana Papin-Zoghbi
  url: https://www.reuters.com/business/healthcare-pharmaceuticals/health-rounds-blood-test-finds-early-ovarian-cancer-2025-08-15/
  why: CEO and co-founder quoted on clinical development.

keywords

• ovarian cancer blood test symptomatic women
• early ovarian cancer biomarkers
• ovarian cancer liquid biopsy
• lipidomics cancer diagnostics
• multiomics ovarian cancer test
• ovarian cancer diagnostic research

voice

• mission driven
• scientific
• forward looking

signals

• text: A hospital is enrolling symptomatic patients in ovarian cancer diagnostic studies.
• text: A laboratory is evaluating multi-omics biomarkers for earlier detection and has clinical validation capacity.

stack

• liquid chromatography-mass spectrometry

hiring

• LC-MS Research Associate I (Contract)

pricing

motion

channels

• clinical partnerships
• scientific conferences
• publications
• press

confidence

Founders

• name: Oriana Papin-Zoghbi
  title: Founder
  role: Founder
  bio: CEO & Co-Founder AOA Dx Inc. Passionate about Women's Health.
• name: Alex Fisher
  title: Founder/COO
  role: COO
  bio: Chief Operating Officer & Co-Founder of AOA Dx. Passion about improving women's health.
• name: Anna Jeter
  title: Founder
  role: Founder
  bio: Chief Business Officer & Co-Founder